Latest news with #Ebidta
Business Times
6 days ago
- Business
- Business Times
Marina Bay Sands H1 revenue rises 17% to US$2.6 billion as travel spend in Asia expands
[SINGAPORE] Net revenue for Marina Bay Sands (MBS) rose 17 per cent to US$2.6 billion (S$3.3 billion) in the first half of 2025, up from US$2.2 billion (S$2.8 billion) for the same period in 2024. The casino resort operator's parent company, Las Vegas Sands (LVS) said on Thursday (Jul 24) that MBS delivered 'record financial and operating performance'. The company drew down S$1.1 billion to fund the payment of the land premium for the US$8 billion MBS expansion. Revenue from rooms for Q2 grew 8 per cent year on year to US$134 million, though hotel occupancy dropped by 0.3 percentage point to 95 per cent across the same period. The average daily room rate rose 11.4 per cent, up to US$888 million, resulting in a revenue per available room of US$844 million compared to US$759 million in Q2 2024. The company's Ebidta margin for the second quarter grew 4.9 percentage points to 55.3 per cent. To be completed in 2030, the new luxury hotel tower is set to have 570 suites and is expected to feature boutiques, gaming and wellness amenities. It will be 55 storeys tall and showcase a 76,000 square foot 'Skyloop'.
&w=3840&q=100)
Business Standard
7 days ago
- Business
- Business Standard
Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY
Cipla Q1FY26 results preview: India's leading pharmaceutical company, Cipla, is expected to report moderate year-on-year (Y-o-Y) growth in both profit and revenue. However, on a quarterly basis, while profit is likely to increase, revenue may see a slight decline. This is due to strong growth in One Africa and EU/Rest of the World regions, while partially offset by muted US sales due to pricing pressure and limited product approvals. The pharma major is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025. According to brokerages tracked by Business Standard, Cipla may see its average revenue increase by 5.6 per cent year-on-year (Y-o-Y) to ₹7,071 crore as against ₹6,694 crore in the June quarter of FY25. Similarly, on a quarter-on-quarter (Q-o-Q) basis, the topline may grow by 5 per cent compared to ₹6,730 crore in Q4FY25. The pharma major is expected to report an average profit after tax (PAT) of ₹1,208 crore for the June quarter, against ₹1,178 crore in Q1FY25, implying an increase of only 2.6 per cent Y-o-Y for Q1FY26. On a quarterly basis, profits could fall by a marginal 1.12 per cent. The company reported a profit after tax (PAT) of ₹1,222 crore in the March quarter of FY25. According to brokerage forecasts, the company's earnings before interest, tax, depreciation and amortisation (Ebitda) is likely to slightly decrease by 1.3 per cent to ₹1,693 crore in Q1FY25 compared to ₹1,716 crore in the year-ago period. However, on a sequential basis, Ebidta may increase 10 per cent from ₹1,538 crore in the March 2025 quarter. Check List of Q1 results today Here's what the brokerages expect from Cipla Q1FY26 results: Kotak Institutional Equities Despite a slightly modest season, analysts expect Cipla to report a 9 per cent Y-o-Y growth in domestic sales. However, US sales are likely to come in at $221 million, due to slightly higher Lanreotide sales, partially offset by a marginal Quarter-over-Quarter decline in inhaler sales. Kotak also expects strong growth of 16 per cent Y-o-Y in One Africa sales, with South Africa reporting a 15 per cent Y-o-Y growth during the quarter. "In addition, we expect 11 per cent Y-o-Y growth in European Union/Rest of the World sales. Overall, we expect Cipla's Q1FY26 sales to grow 5 per cent Y-o-Y and 5 per cent Q-o-Q," the brokerage said. Motilal Oswal Financial Services The brokerage expects Cipla's US sales to decline 13 per cent Y-o-Y to $219 million for the quarter under review, driven by reduced price of g-Revlimid and limited approvals in Q1FY25. In addition, dosage form (DF) sales are likely to witness moderate growth of 8 per cent Y-o-Y due to weakness in respiratory and anti-diabetes therapies. Analysts are awaiting progress on regulatory measures at the Indore site, an update on the launch of Nilotinib capsules, and the filing of differentiated products with developed markets. Choice Institutional Equities Analysts at Choice Institutional Equities forecast 7.8 per cent Y-o-Y revenue growth, on the back of strong traction in One Africa and moderate growth across other regions. The brokerage expects Ebitda to remain flat due to higher research & development (R&D) spends, with margins contracting 163 bps Y-o-Y. However, PAT is expected to grow 3.7 per cent Y-o-Y. Key monitorables to watch include the management commentary on new biosimilar launches and the anticipated Advair launch. About Cipla Cipla, one of the leading pharmaceutical companies in India, is engaged in the manufacturing, developing, and marketing of a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company's product portfolio includes complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. Cipla has a presence in India, as well as South Africa, North America, and other key regulated and emerging markets. The company operates 47 manufacturing sites across the globe. It produces 50 dosage forms and over 1,500 products across a wide range of therapeutic categories.
&w=3840&q=100)
Business Standard
03-07-2025
- Business
- Business Standard
DMart shares sink 4% as Q1 revenue growth misses street forecast
Shares of Avenue Supermarts Ltd., the operator of the DMart retail chain, fell nearly 4 per cent on Thursday after its first-quarter revenue growth fell short of the street's expectations. The retail chain's stock fell as much as 3.96 per cent during the day to ₹2,417.9 per share, the steepest intraday fall since June 10 this year. The stock pared some losses to trade 3.3 per cent lower at ₹4,239 apiece, compared to a 0.32 per cent advance in Nifty 50 as of 10:20 AM. Shares of the company fell for the second day, and the stock currently trades at 6.8 times the 30-day average trading volume, according to Bloomberg data. The counter has risen 19.4 per cent this year, compared to a 7.6 per cent advance in the benchmark Nifty 50. Avenue Supermarts has a total market capitalisation of ₹2.7 trillion, according to BSE data. Track LIVE Stock Market Updates Here DMart Q1 business update The DMart retail chain reported a 16.2 per cent year-on-year rise in standalone revenue from operations for the quarter ended June 30, 2025. Revenue for the first quarter of the financial year 2025–26 stood at ₹15,932.12 crore, up from ₹13,711.87 crore in the same period last year, it said in an exchange filing on Wednesday. The company reported a revenue of ₹11,584.44 crore in Q1 of fiscal 2023 and a top line of ₹9,806.89 crore in Q1 of 2022. As of June 30, 2025, the total number of DMart stores stood at 424, including one outlet in Sanpada, Navi Mumbai, which is temporarily closed for renovation. JM Financial on DMart Q1 update The revenue growth in the first quarter was 1 per cent below JM Financial's and 2 per cent below consensus estimates, the brokerage said in a note. JM Financial expects a 40 basis points year-on-year (Y-o-Y) dip in Ebidta margin to 8.5 per cent in Q1, despite expectations of a flat gross margin, largely on account of higher operating costs. Store addition largely in line with expectations. Analysts expect the Ebitda to grow 10 per cent year-on-year to ₹1,350 crore in Q1 FY26. Net profit is expected to rise 7 per cent year-on-year to ₹870 crore, primarily impacted by higher depreciation expenses and lower other income, JM Financial said. About Avenue Supermarts (DMart)
&w=3840&q=100)
Business Standard
23-04-2025
- Business
- Business Standard
This defence related stock nears record high; zooms 50% in 2 months
Solar Industries India share price today: Shares of Solar Industries India hit a nine-month high of ₹13,140.55, up 2.4 per cent on the BSE in Wednesday's intra-day trade. The stock price of India's largest manufacturer of industrial explosives is trading close to its all-time high level of ₹13,300, which it touched on July 11, 2024. In the past two weeks, the market price of Solar Industries surged 21 per cent. Further, in the last two months, it zoomed 50 per cent from a level of ₹8,756 on the BSE. Healthy 9MFY25 results Solar Industries reported a highest ever nine monthly earnings before interest, taxes, depreciation, and amortization (Ebidta) and profit after tax (PAT) of ₹1,485 crore and ₹942 crore, respectively, registering a growth of 43 per cent and 49 per cent in nine months (April to December) of the financial year of 2024-25 (9MFY25). Net revenue grew 21 per cent year-on-year (Y-o-Y) at ₹5,374 crore during the period. While domestic demand has been subdued due to the general and state elections in many parts and the heavy monsoon season, the company's long-term growth trajectory remains robust, driven by strategic diversification. The international business has delivered an exceptional third-quarter performance, growing 21 per cent Y-o-Y and reaching a best-ever ₹758 crore in revenue. Strong Order Book Positions Solar Industries has a strong order book position of nearly ₹10,000 crore. As of December 31, 2024, the company has the highest ever order book of over ₹7,100 crore. Last month, on March 4, 2025, Solar Defence and Aerospace Limited (formerly known as Economic Explosives Limited) a wholly owned subsidiary of Solar Industries India Limited signed a contract worth ₹239 crore with Ministry of Defence, Government of India for the supply of multi mode hand grenade, to be delivered over a period of one year. Earlier, on February 28, Solar Industries and its subsidiary received export orders worth ₹ 2,150 crore for the supply of defence products, to be delivered over six years. On February 5, Ministry of Defence inked contracts with economic explosive for the procurement of Area Denial Munition (ADM) Type-1 (DPICM) and High Explosive Pre Fragmented (HEPF) Mk-1 (Enhanced) rockets respectively for PINAKA Multiple Launcher Rocket System (MLRS), the biggest contract in the history of Solar Group. Defence Research and Development Organisation (DRDO) has nominated Economic Explosives Limited (EEL) as the production agency for all the variations of the Pinaka Rocket System. This contract will not only drive revenue growth of defence products, but also open new opportunities and establish the company's prominence in indigenous defence manufacturing, the management said. Revolution in India's defence market The government's active promotion of private sector participation, driven by the "Atmanirbhar Bharat" initiative, is fueling modernisation and innovation. Solar Industries, recognising the potential of this sector early on, strategically made a huge investment in building its defence capabilities, securing an early mover advantage. Solar's defence business quarterly performance picked up the splendid growth of 570 per cent Y-o-Y, reaching the highest ever Defence revenue in the quarter at ₹409 crore. The strong results and strong orders in hand are providing the necessary thrust for upcoming initiatives. On this backdrop company has signed an MOU with the Government of Maharashtra for investing ₹12,700 crore in the next 10 years to establish an Anchor Mega Project. Exports of subsystems and components present a sizeable opportunity There has been a rising interest among global defence original equipment manufacturers (OEM) to look at domestic public and private defence manufacturers to outsource and procure subsystems for defence equipment, according to Elara Securities. Currently, the US, France and Armenia are the top three export countries for India; domestic companies to date have supplied weapons and equipment, such as the 155mm artillery guns, Akash air defence missile, Pinaka multi-launch rocket system, the BrahMos missile, artillery guns, Dornier-228 aircraft, radars, armored vehicles, fuselage and wings for aircraft and helicopters, bulletproof vests, night vision equipment and electronics, the brokerage firm said in March month defense sector report. India's defence exports have increased significantly in recent years, reaching a record ₹21,000 crore in FY24, according to the defence ministry. This is a 33 per cent increase from the previous fiscal year. India has set a defence exports target of ₹30,000 crore by FY26. In this context, the new $850 billion plan by the European Union (EU) provides a major opportunity for domestic public and private defence companies, especially for exports of subsystems and components to EU OEM, analysts at the brokerage firm said. About Solar Industries Solar Industries India, along with its subsidiaries, manufactures bulk explosives, packaged explosives and initiating systems, which find application in the mining, infrastructure and construction industries. The Group forayed into the defence sector in 2010 and diversified into the manufacturing of propellants for missiles and rockets, warheads and warhead explosives. At present, there are 32 manufacturing plants across nine states in India, in addition to seven overseas units in Zambia, Ghana, Nigeria, Turkey, South Africa, Tanzania and Indonesia.
